Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
April 08, 2024 02:00 ET
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Secures European Patent for its iM-TCR Technology
April 04, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 02:30 ET
|
Medigene AG
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program...
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to report full year 2023 financial results on March 28, 2024
March 18, 2024 10:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will...
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
March 06, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
March 04, 2024 02:00 ET
|
Medigene AG
Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
February 29, 2024 06:00 ET
|
Medigene AG
Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty...
Medigene to Present at Upcoming Conferences
February 19, 2024 08:00 ET
|
Medigene AG
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
February 12, 2024 08:00 ET
|
Medigene AG
Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T...